These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 15182760)

  • 1. Experimental animal model for anthracycline-induced heart failure.
    Perik PJ; van den Berg MP; de Vries EG; van Veldhuisen DJ
    Eur J Heart Fail; 2004 Jun; 6(4):375-6. PubMed ID: 15182760
    [No Abstract]   [Full Text] [Related]  

  • 2. Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents.
    Simůnek T; Klimtová I; Kaplanová J; Mazurová Y; Adamcová M; Sterba M; Hrdina R; Gersl V
    Eur J Heart Fail; 2004 Jun; 6(4):377-87. PubMed ID: 15182761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dexrazoxane in anthracycline induced cardiotoxicity and extravasation].
    Goey AK; Schellens JH; Beijnen JH; Huitema AD
    Ned Tijdschr Geneeskd; 2010; 154():A1155. PubMed ID: 20619024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotoxicity debated for anthracyclines and trastuzumab in breast cancer.
    Brower V
    J Natl Cancer Inst; 2013 Jun; 105(12):835-6. PubMed ID: 23733910
    [No Abstract]   [Full Text] [Related]  

  • 6. Doxorubicin-induced cardiomyopathy.
    Swain SM
    N Engl J Med; 1999 Feb; 340(8):654; author reply 655. PubMed ID: 10049087
    [No Abstract]   [Full Text] [Related]  

  • 7. Anthracycline cardiotoxicity in children.
    Kremer LC; Caron HN
    N Engl J Med; 2004 Jul; 351(2):120-1. PubMed ID: 15247351
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
    Pouillart P
    Cancer Treat Rev; 2004 Nov; 30(7):643-50. PubMed ID: 15531396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction and prevention of chemotherapy-induced cardiomyopathy: can it be done?
    Granger CB
    Circulation; 2006 Dec; 114(23):2432-3. PubMed ID: 17146002
    [No Abstract]   [Full Text] [Related]  

  • 10. Dexrazoxane in anthracycline extravasation.
    Langer SW; Sehested M; Jensen PB; Buter J; Giaccone G
    J Clin Oncol; 2000 Aug; 18(16):3064. PubMed ID: 10944144
    [No Abstract]   [Full Text] [Related]  

  • 11. Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity.
    Herman EH; Ferrans VJ
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):15-21. PubMed ID: 9768819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dexrazoxane: a second look. Prevention of anthracycline cardiotoxicity: useful for some patients.
    Prescrire Int; 2008 Oct; 17(97):195. PubMed ID: 19534047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients.
    Anderson B
    Pediatr Blood Cancer; 2005 Jun; 44(7):584-8. PubMed ID: 15700251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries.
    Langer SW; Jensen PB; Sehested M
    Cardiovasc Toxicol; 2007; 7(2):151-3. PubMed ID: 17652821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview and historical development of dexrazoxane.
    Hellmann K
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):48-54. PubMed ID: 9768824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies for reduction of anthracycline cardiac toxicity.
    Speyer J; Wasserheit C
    Semin Oncol; 1998 Oct; 25(5):525-37. PubMed ID: 9783592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
    Jensen BV
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.
    Wouters KA; Kremer LC; Miller TL; Herman EH; Lipshultz SE
    Br J Haematol; 2005 Dec; 131(5):561-78. PubMed ID: 16351632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane.
    Bernitsas E; Wei W; Mikol DD
    Ann Neurol; 2006 Jan; 59(1):206-9. PubMed ID: 16374818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular toxicities of cancer chemotherapy.
    Bonita R; Pradhan R
    Semin Oncol; 2013 Apr; 40(2):156-67. PubMed ID: 23540741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.